Terazosin Capsule
Product Images NDC 27241-288

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 27241-288). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg (Terazosin 10mg)

Terazosin Capsules, USP 10 mg oral capsules label marketed by Ajanta Pharma USA Inc. The label states a package of 100 capsules, NDC 27241-291-01. Storage instructions include temperature guidelines and child-resistant packaging details. The label includes a barcode and space for lot and expiration dates.*

FDA Label Image

1mg (Terazosin 1mg)

Label for Terazosin Capsules, USP 1 mg by Ajanta Pharma USA Inc. The label indicates a package of 100 oral capsules with terazosin hydrochloride equivalent to 1 mg terazosin each. It includes storage instructions, child-resistant packaging details, and a barcode. Manufacturer location is Bridgewater, NJ, with capsules made in India.*

FDA Label Image

2mg (Terazosin 2mg)

Terazosin Capsules, USP 2 mg oral capsules carton label by Ajanta Pharma USA Inc. The label states the package contains 100 capsules and is child-resistant. Storage instructions specify 20°-25°C with allowed excursions. Includes NDC 27241-289-01 and a barcode. The package is marked Rx only.*

FDA Label Image

5mg (Terazosin 5mg)

Label for Terazosin Capsules, USP 5 mg, oral capsules, marketed by Ajanta Pharma USA Inc. The label indicates a package size of 100 capsules, with storage instructions, child-resistant packaging notes, and space for lot and expiration dates. The label includes the NDC 27241-290-01 and a barcode.*

FDA Label Image

Figure1 (Terazosin Fig1)

Two line graphs showing clinical trial results for Terazosin versus placebo. The first graph plots mean change in total symptom score from baseline over three months, showing a greater decrease for Terazosin than placebo. The second graph shows mean increase in peak flow rate (mL/sec) from baseline over three months, with higher increases for Terazosin compared to placebo. Sample sizes (N) are indicated for both groups.*

FDA Label Image

Figure2 (Terazosin Fig2)

A line graph showing mean change from baseline over time in months from 0 to 30. The y-axis displays mean change values ranging from 0 to -7. Data points are marked with asterisks indicating statistical significance at several early time points.*

FDA Label Image

Figure3 (Terazosin Fig3)

Line graph showing mean change from baseline in mL/sec over a 30-month period. The x-axis represents months from 0 to 30 and the y-axis represents mean change from baseline ranging from 0 to 4.5 mL/sec. Data points are plotted with error bars, showing a general upward trend with marked values at several points.*

FDA Label Image

Structure (Terazosin Structure)

Chemical structure of terazosin showing its detailed molecular framework, including multiple rings and functional groups labeled with elements such as nitrogen, oxygen, and methyl groups, with a notation for hydrochloride hydrate (HCl·1.2H2O).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.